Durham, NC (February 1, 2018) – Parion Sciences, a clinical stage company dedicated to developing novel therapies for the treatment of pulmonary and ocular diseases, today announced the appointment of Alison Church, M.D., as Chief Medical Officer.
Demonstrates ongoing commitment to innovation in ophthalmics for Shire
P-321 is a Phase 2 investigational topical treatment for dry eye disease
Lexington, Massachusetts, and Durham, North Carolina, US – May 1, 2017 – Shire plc (LSE: SHP, NASDAQ: SHPG) and Parion Sciences, Inc. today announced they have entered into an agreement granting Shire exclusive worldwide rights to develop and commercialize P-321. Shire will lead development of P-321, an investigational epithelial sodium channel (ENaC) inhibitor for the potential treatment of dry eye disease in adults, with the opportunity for Parion to co-fund.
First-in-human trial encouraging, identifies agent that is associated with signs of improvement in tear function
Clinical Data to be presented for a novel device for transnasal delivery of a pulmonary aerosol in children with Cystic Fibrosis
Durham, NC (October 25, 2016) – Parion Sciences, a company dedicated to the development of novel treatments for pulmonary and ocular diseases, announced that an abstract from its pulmonary research and development efforts will be presented at the 30th Annual North American Cystic Fibrosis Conference (NACFC) in Orlando, Florida, October 27 through 29, 2016.
First Patient Enrolled in P-321-202 Clinical Trial
Durham, NC (July 26, 2016) – Parion Sciences, a company dedicated to the development of novel treatments for pulmonary and ocular diseases, announced today it has initiated a phase 2 clinical trial of P-321 Ophthalmic Solution in patients with Dry Eye Disease (DED). P-321 is a potent inhibitor of the epithelial sodium channels (ENaC) on the ocular surface, and is expected to restore the tear film on the ocular surface in those patients with dry eye disease. Earlier this year the results of a Phase 1/2a safety, tolerability, and pharmacokinetics study in subjects with dry eye were presented.
Data on P-321 from clinical research to be presented on May 3rd
Durham, NC (May 2, 2016) – Parion Sciences, a company dedicated to the development of novel treatments for pulmonary and epithelial diseases, announced today the presentation of a poster containing clinical data for the development stage dry eye treatment P-321. The presentation is a review of the results from a clinical trial of P-321 versus placebo in patients with dry eye disease and will be presented at the Association for Research in Vision and Ophthalmology (ARVO) in Seattle, Washington on May 3rd, 2016.
LIBOURNE FRANCE and DURHAM NC (January 19, 2016) — Ceva Santé Animale and Zoion Pharma Inc. announced today that they have entered into a collaboration to develop an epithelial sodium channel (ENaC) inhibitor to treat veterinary ocular surface diseases characterized by a lack of surface hydration, such as keratoconjunctivitis sicca (KCS) commonly called dry eye. Under the agreement, Ceva gains worldwide development and commercial rights to ZP-1 (P-1046). ZP-1 has successfully completed a proof-of-concept clinical trial in canine KCS. ZP-1 (P-1046) was originally discovered by Parion Sciences, Inc. and licensed to Zoion Pharma for veterinary use.
- Data from preclinical and clinical research on P-1037(VX-371) to be presented
- Additional data presentation includes a review of a novel in silico approach towards identification of CFTR correctors
Durham, NC (October 5, 2015) – Parion Sciences, a company dedicated to the development of novel treatments for pulmonary and ocular diseases, announced that 3 abstracts from its pulmonary research and development efforts will be presented at the 29th Annual North American Cystic Fibrosis Conference (NACFC) in Phoenix Arizona, October 8 through 10, 2015. Data to be presented on P-1037 (also known as VX-371) includes preclinical models as well as a review of the clinical data. A review of a novel in silico model to identify new CFTR correctors
Drug Safety Monitoring Board Recommends Expansion of Trial Population to Include 12 to 17 Year Old People with CF
Durham, NC (September 10, 2015) – Parion Sciences, a company dedicated to the development of novel treatments for pulmonary and ocular diseases, announced today that the CLEAN-CF enrollment criteria for the study of P-1037 would be expanded to include people with Cystic Fibrosis (CF) between the ages of 12 and 17 years of age. The trial had previously enrolled people with CF age 18 and above only. The expansion of the age criteria for enrollment was based on a pre-specified safety review by the Data Monitoring Committee (DMC).
– ENaC inhibition aims to restore or improve hydration of cell surfaces in the lungs to improve lung function –
– Parion to receive $80 million up-front payment with potential for additional development and regulatory
milestones and royalty payments –
BOSTON and DURHAM, NC — Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and Parion Sciences today announced that the companies will collaborate to develop investigational epithelial sodium channel (ENaC) inhibitors for the potential treatment of cystic fibrosis (CF) and other pulmonary diseases. Under the agreement, Vertex gains worldwide development and commercial rights to Parion’s investigational ENaC inhibitors, including P-1037 and P-1055, for CF and other pulmonary diseases. P-1037 is currently being evaluated in an exploratory Phase 2a study in people with CF, regardless of genotype, and Vertex and Parion plan to begin an additional Phase 2a study that adds P-1037 to treatment with the investigational combination of lumacaftor and ivacaftor for people with CF who have two copies of the F508del mutation. Parion will receive an $80 million up-front payment from Vertex with the potential to receive additional development and regulatory milestone payments and tiered royalties related to P-1037 and P-1055 in CF and other pulmonary diseases.